Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy

Biotechnology and Bioengineering

Volumn 111, Issue 8, 2014, Pages 1513-1520

  Jayaraman, Jayapriya ^a   Wu, Jiemin ^a   Brunelle, Molly C ^a   Cruz, Anna Marie M ^a   Goldberg, Deborah S ^b   Lobo, Brian ^b   Shah, Ambarish ^b   Tessier, Peter M ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Aggregation; Formulation; MAb; Solubility; Stability; Viscosity

Indexed keywords

AGGLOMERATION; CONVERGENCE OF NUMERICAL METHODS; MONOCLONAL ANTIBODIES; NANOPARTICLES; PLASMONS; SOLUBILITY; VISCOSITY;

ANTIBODY CONCENTRATION; FORMULATION; INTERACTION PARAMETERS; INTERPARTICLE DISTANCES; MAB; SELF-ASSOCIATION PROPENSITY; THERAPEUTIC MONOCLONAL ANTIBODIES; THREE ORDERS OF MAGNITUDE;

ASSOCIATION REACTIONS;

GOLD NANOPARTICLE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; IMMOBILIZED ANTIBODY; IMMUNOGLOBULIN G; NANOPARTICLE;

ADSORPTION; ANALYTIC METHOD; ARTICLE; DIFFUSION; LIGHT SCATTERING; MEASUREMENT; SELF INTERACTION NANOPARTICLE SPECTROSCOPY; SPECTROSCOPY; CHEMISTRY; HUMAN; LIGHT; RADIATION SCATTERING;

ANTIBODIES, IMMOBILIZED; ANTIBODIES, MONOCLONAL; DIFFUSION; HUMANS; IMMUNOGLOBULIN G; LIGHT; NANOPARTICLES; SCATTERING, RADIATION; SPECTRUM ANALYSIS;

EID: 84903270626     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25221     Document Type: Article

References (27)

1. Brekke OH, Sandlie I. 2003. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52-62.
2. Buijs J, Lichtenbelt JW, Norde W, Lyklema J. 1995. Adsorption of monoclonal IgGs and their F(ab')2 fragments onto polymeric surfaces. Colloids Surf B 5(1-2):11-23.
3. Burckbuchler V, Mekhloufi G, Giteau AP, Grossiord JL, Huille S, Agnely F. 2010. Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions. Eur J Pharm Biopharm 76(3):351-356.
4. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: High-throughput analysis using the diffusion interaction parameter. Biophys J 103(1):69-78.
5. Correia IR. 2010. Stability of IgG isotypes in serum. mAbs 2(3):221-232.
6. Daugherty AL, Mrsny RJ. 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58(5-6):686-706.
7. De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490.
8. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266-25279.
9. Lee CC, Perchiacca JM, Tessier PM. 2013. Toward aggregation-resistant antibodies by design. Trends Biotechnol 31(11):612-620.
10. Lehermayr C, Mahler HC, Mader K, Fischer S. 2011. Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J Pharm Sci 100(7):2551-2562.
11. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. 2011. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 84:41-61.
12. Nezlin R. 2010. Interactions between immunoglobulin G molecules. Immunol Lett 132(1-2):1-5.
13. Perchiacca JM, Tessier PM. 2012. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng 3:263-286.
14. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. 2013. Immunogenicity of therapeutic proteins: Influence of aggregation. J Immunotoxicol 11(2):99-109.
15. Reichert JM. 2012. Marketed therapeutic antibodies compendium. mAbs 4(3):413-415.
16. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
17. Saito S, Hasegawa J, Kobayashi N, Kishi N, Uchiyama S, Fukui K. 2012. Behavior of monoclonal antibodies: Relation between the second virial coefficient (B(2)) at low concentrations and aggregation propensity and viscosity at high concentrations. Pharm Res 29(2):397-410.
18. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. 2010. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 99(1):82-93.
19. Saluja A, Fesinmeyer RM, Hogan S, Brems DN, Gokarn YR. 2010. Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 99(8):2657-2665.
20. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20(6):708-714.
21. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
22. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 21(7):1087-1093.
23. Sule SV, Cheung JK, Antochshuk V, Bhalla AS, Narasimhan C, Blaisdell S, Shameem M, Tessier PM. 2012. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength. Mol Pharm 9(4):744-751.
24. Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. 2013. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 10(4):1322-1331.
25. Sule SV, Sukumar M, Weiss WF, Marcelino-Cruz AM, Sample T, Tessier PM. 2011. High-throughput analysis of concentration-dependent antibody self-association. Biophys J 101(7):1749-1757.
26. Yadav S, Shire SJ, Kalonia DS. 2010. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 99(12):4812-4829.
27. Yadav S, Shire SJ, Kalonia DS. 2012. Viscosity behavior of high-concentration monoclonal antibody solutions: Correlation with interaction parameter and electroviscous effects. J Pharm Sci 101(3):998-1011.